Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGENERATE-PD
2023-506519-16-00Phase 2Authorised
- Sponsor
- AskBio
- Start
- Aug 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial of ametefgene parvec in Parkinson's disease (PD) (2 arms), sponsored by AskBio. Primary endpoint: Change in normalized Good ON time. Planned start Aug 2024; status: authorised.
02
Drugs
ametefgene parvec
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2023-506519-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506519-16-00.